Pre-order Enquiry
Request Free Sample
Global Anticancer Drugs Market Research Report 2021
SKU ID : QYR-17139648 | Publishing Date : 11-Jan-2021 | No. of pages : 90
Antineoplastic drugs, also known as anticancer drugs, anti-malignant drugs, refer to drugs for the treatment of malignant tumors.
Simply put, there are chemotherapy drugs and biological agents. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of tumors; the invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry, and genetic engineering have accelerated the process of drug development; research and development of anti-tumor drugs have been Enter a new era.
The global Anticancer Drugs market was valued at US$ 84270 million in 2019 and is expected to reach US$ 108880 million by the end of 2026, growing at a CAGR of 3.7% during 2021-2026.
This report focuses on Anticancer Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Anticancer Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Anticancer Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Cytotoxic Drugs (Alkylating Agents, and Antimetabolites)
Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors)
Hormonal Drugs
Segment by Application
Lung Cancer
Breast Cancer
Leukemia
Colorectal Cancer
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
F. Hoffmann-La Roche Ltd
Eli Lilly and Company
CELGENE CORPORATION
Novartis AG
Pfizer Inc
Amgen Inc
Bayer AG
AstraZeneca
Takeda Pharmaceutical Company Limited
Merck & Co.
Simply put, there are chemotherapy drugs and biological agents. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of tumors; the invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry, and genetic engineering have accelerated the process of drug development; research and development of anti-tumor drugs have been Enter a new era.
The global Anticancer Drugs market was valued at US$ 84270 million in 2019 and is expected to reach US$ 108880 million by the end of 2026, growing at a CAGR of 3.7% during 2021-2026.
This report focuses on Anticancer Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Anticancer Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Anticancer Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Cytotoxic Drugs (Alkylating Agents, and Antimetabolites)
Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors)
Hormonal Drugs
Segment by Application
Lung Cancer
Breast Cancer
Leukemia
Colorectal Cancer
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
F. Hoffmann-La Roche Ltd
Eli Lilly and Company
CELGENE CORPORATION
Novartis AG
Pfizer Inc
Amgen Inc
Bayer AG
AstraZeneca
Takeda Pharmaceutical Company Limited
Merck & Co.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Request Sample
Request Discount
